Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 25, 2012, Pages 3051-3057

  Schneider, Bryan P ^a   Zhao, Fengmin ^b   Wang, Molin ^b   Stearns, Vered ^c   Martino, Silvana ^d   Jones, Vicky ^e   Perez, Edith A ^f   Saphner, Tom ^g   Wolff, Antonio C ^c   Sledge, George W ^a   Wood, William C ^h   Davidson, Nancy E ⁱ   Sparano, Joseph A ^j  

^a Indiana Cancer Pavilion   (United States)

^b ECOG   (United States)

^c ECOG   (United States)

^d SWOG   (United States)

^e Cancer and Leukemia Group B   (United States)

^f North Central Cancer Treatment Group Rochester   (United States)

^g ECOG   (United States)

^h ECOG   (United States)

ⁱ ECOG   (United States)

^j ECOG   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE; RECURRENCE FREE SURVIVAL; TUMOR VOLUME;

EID: 84865718734     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.8446     Document Type: Article

References (30)

1. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
2. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
3. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
4. Bria E, Nistico C, Cuppone F, et al: Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 106:2337-2344, 2006
5. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649, 2008
6. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
7. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 24:1633-1642, 2006
8. Swain SM, Arezzo JC: Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management. Clin Adv Hematol Oncol 6:455-467, 2008
9. Cavaletti G, Tredici G, Braga M, et al: Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133:64-72, 1995
10. Flatters SJ, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain 122:245-257, 2006
11. Jimenez-Andrade JM, Peters CM, Mejia NA, et al: Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett 405:62-67, 2006
12. Nakata T, Yorifuji H: Morphological evidence of the inhibitory effect of taxol on the fast axonal transport. Neurosci Res 35:113-122, 1999
13. Persohn E, Canta A, Schoepfer S, et al: Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41:1460-1466, 2005
14. Peters CM, Jimenez-Andrade JM, Kuskowski MA, et al: An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 1168:46-59, 2007
15. Raine CS, Röytta M, Dolich M: Microtubule-mitochondrial associations in regenerating axons after taxol intoxication. J Neurocytol 16:461-468, 1987
16. Theiss C, Meller K: Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res 299:213-224, 2000
17. Witte H, Neukirchen D, Bradke F: Microtubule stabilization specifies initial neuronal polarization. J Cell Biol 180:619-632, 2008
18. Wolf S, Barton D, Kottschade L, et al: Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 44:1507-1515, 2008
19. Park SB, Krishnan AV, Lin CS, et al: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081-3094, 2008
20. Gogas H, Shapiro F, Aghajanian C, et al: The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61:22-26, 1996
21. Rowinsky EK, Chaudhry V, Cornblath DR, et al: Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107-115, 1993
22. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993 (4 suppl 3)
23. Schneider B, Li L, Miller K, et al: Genetic associations with taxane-induced neuropathy by genome wide association study (GWAS) in E5103. J Clin Oncol 29:80s, 2011 (suppl; abstr 1000)
24. Kroetz DL, Baldwin RM, Owzar K, et al: Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. J Clin Oncol 28:238s, 2010 (suppl; abstr 3021)
25. Sucheston LE, Zhao H, Yao S, et al: Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130:993-1002, 2011
26. Moreno-Aspitia A, Dueck A, Patel T, et al: Paclitaxel-related peripheral neuropathy associated with improved outcome of patients with early stage HER2+ breast cancer who did not receive trastuzumab in the N9831 clinical trial. San Antonio Breast Cancer Symposium, 2009
27. Akerley W, Herndon JE, Egorin MJ, et al: Weekly, high-dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-2486, 2003
28. US Department of Health and Human Services: National Guideline 1Clearinghouse. http://www.guideline.gov/
29. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
30. Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551, 2005